



NDA 21-310

Watson Laboratories, Inc.
Attention: Dorothy A. Frank, M.S., R.A.C.
Executive Director, Proprietary Regulatory Affairs
417 Wakara Way
Salt Lake City, UT 84108

Dear Ms. Frank:

Please refer to your new drug application (NDA) dated January 12, 2001, received January 16, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Alora (estradiol transdermal system) 0.025 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day.

Your submission of February 5, 2002, constituted a complete response to our January 18, 2002, action letter.

This new drug application provides for 1) addition of a 0.025 mg/day strength product and 2) addition of an indication for the prevention of postmenopausal osteoporosis for all strengths.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, text for the patient package insert) and submitted draft labeling (pouch and carton labels submitted on November 15, 2001). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 21-310." Approval of this submission by FDA is not required before the labeling is used.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 FR 66632). We are waiving the pediatric study requirement for this action on this application.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81). All 15-day alert reports, periodic (including quarterly) adverse drug experience reports, field alerts, annual reports, supplements, and other submissions should be addressed to the original NDA, NDA 20-655, for this drug product, not to this NDA. In the future, do not make submissions to this NDA except for the final printed labeling requested above.

If you have any questions, call Samuel Y. Wu, Pharm.D., Regulatory Project Manager, at 301-827-6416.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

David Orloff
4/5/02 01:11:46 PM